Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients.

@article{Lobmeyer2011PolymorphismsIG,
  title={Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients.},
  author={Maximilian T. Lobmeyer and Liewei Wang and Issam Zineh and Stephen T. Turner and John Gums and Arlene B. Chapman and Rhonda M. Cooper-Dehoff and Amber Beitelshees and Kent R. Bailey and Eric Boerwinkle and Carl J Pepine and Julie A. Johnson},
  journal={Pharmacogenetics and genomics},
  year={2011},
  volume={21 1},
  pages={42-9}
}
OBJECTIVES The G-protein-coupled receptor kinases (GRKs) GRK2 and GRK5 are important regulators of β-adrenergic signaling. This study characterized single-nucleotide polymorphisms (SNPs) in the GRK2 gene (ADRBK1) and determined if these and a GRK5 Gln41Leu polymorphism affect the blood pressure (BP) response to atenolol or hydrochlorothiazide or adverse cardiovascular outcomes in hypertensives. METHODS ADRBK1 regions were sequenced for 48 individuals. Putative functional SNPs were tested for… CONTINUE READING